Phenylacetic Acid
(Synonyms: 苯乙酸,NSC 125718, Phenylethanoic acid, α-Toluic acid) 目录号 : GC40414
苯乙酸是一种含有苯基官能团和羧酸官能团的有机化合物。
Cas No.:103-82-2
Sample solution is provided at 25 µL, 10mM.
Phenylacetic acid is an organic compound containing a phenyl functional group and a carboxylic acid functional group. It is a white solid with a disagreeable odor.
The survival rate of HL60 cells was decreased, the secretion of PDGF-β was decreased,HL60 cells were blocked in G0/G1 phase, the level of Bcl-2 protein was decreased, and the level of Bax protein was increased after Phenylacetic Acid treatment at different concentrations[4]. Phenylacetic acid inhibited the proliferation of CNE-2 cells to some extent.Flow cytometry showed that cell apoptosis occurred after treatment, the increase of G0-G1 phase cells and the decrease of phenylacetic acid in S phase cells inhibited the growth of CNE-2 cells in a dose and time dependent manner.The cell block in G1 phase can significantly reduce the S phase[1]. Phenylacetic Acid inhibited the proliferation of SMMC-7721 cells in a time-dependent and dose-dependent manner[2]. Phenylacetic Acid can inhibit cell proliferation cycle in G1 phase, reduce DNA synthesis and inhibit cell proliferation. The mechanism of action is that Phenylacetic Acid inhibits the functional expression of certain effector protein RNA in G1 phase of BXPC-3 cell cycle[5]. Phenylacetic acid inhibited the growth of A549 cells, which might be realized by inhibiting the cell cycle in G1/G0 phase and inducing apoptosis[7].
Phenylacetic Acid can inhibit the growth of salivary gland tumors by inhibiting ERK/MAPK pathway and reduce cell proliferation, which is expected to be used in drug therapy of salivary gland tumors[3]. In vivo Phenylacetic Acid can inhibit tumor growth and induce apoptosis of glioma C6 cells[6].
References:
[1]. Zhao Jin,and Chen Liangxin." Effects of sodium phenylacetic acid on human nasopharyngeal carcinoma cells CNE-2." Guangzhou Chemical Industry 43.24(2015):117-118+123.
[2]. Wang Y. Inhibitory effect of phenylacetic acid on the proliferation of hepatocellular carcinoma cells SMMC-7721 and its correlation with the expression of ADAR1 [D]. Jilin University,2013.
[3]. Shang Wenjun, et al." Effects of sodium phenylacetate, an ERK pathway inhibitor, on salivate gland tumors in transgenic mice." Chinese Journal of Oral and Maxillofacial Surgery 11.05(2013):359-364.
[4]. Yang Li, et al." Sodium phenylacetic acid induces apoptosis of human leukemia cell HL60 and its mechanism." Shandong Medical Journal 50.40(2010):60-61.
[5]. Wang Y, et al." Inhibitory effect of phenylacetic acid on DNA synthesis in pancreatic cancer cells." Journal of Jilin University (Med) 37.05(2011):808-811+971. doi:10.13481/j.1671-587x.2011.05.056.
[6]. Yang Chao-hua, et al." Effects of phenylacetic acid on apoptosis of glioma C6 cells in rats." Western Medicine 21.11(2009):1841-1843.
[7]. Zhang Li, Li QQ, et al." Effects of sodium phenylacetic acid on the growth of A549 lung cancer cells." Journal of Wuhan University (Med Edition).02(2006):249-252.
苯乙酸是一种含有苯基官能团和羧酸官能团的有机化合物。它是一种带有难闻气味的白色固体。
HL60细胞存活率降低,PDGF-β分泌减少,HL60细胞阻滞于G0/G1期,Bcl-2蛋白水平降低,Bax蛋白水平升高不同浓度苯乙酸处理[4]。苯乙酸在一定程度上抑制了CNE-2细胞的增殖。流式细胞术显示处理后细胞发生凋亡,G0-G1期细胞增多,S期细胞苯乙酸减少,抑制了CNE-2细胞的生长。呈剂量和时间依赖性。G1期细胞块可显着减少S期[1]。苯乙酸以时间依赖和剂量依赖的方式抑制SMMC-7721细胞的增殖[2]。苯乙酸能抑制G1期细胞增殖周期,减少DNA合成,抑制细胞增殖。作用机制是苯乙酸抑制BXPC-3细胞周期G1期某些效应蛋白RNA的功能性表达[5]。苯乙酸抑制A549细胞的生长,可能是通过抑制G1/G0期细胞周期,诱导细胞凋亡来实现的[7]。
苯乙酸通过抑制ERK/MAPK通路,减少细胞增殖,从而抑制唾液腺肿瘤的生长,有望用于唾液腺肿瘤的药物治疗[3]。体内苯乙酸可抑制肿瘤生长并诱导胶质瘤C6细胞凋亡[6]。
| Cell experiment [1]: | |
|
Cell lines |
HL60 cell |
|
Preparation Method |
The cells grew into the logarithmic phase and were inoculated in 96-well plates with 200H1 / well and the control group (without induced acetic Acid) and Phenylacetic Acid group.The experimental group included HL60 cells induced by different concentration of Phenylacetic Acid(5, 10, 15 mmol/L) and the induction time group (12, 24, 48h). |
|
Reaction Conditions |
5, 10, 15 mmol/L Phenylacetic Acid for 12, 24, 48h |
|
Applications |
The survival rate of HL60 cells was decreased, the secretion of PDGF-β was decreased,HL60 cells were blocked in G0/G1 phase, the level of Bcl-2 protein was decreased, and the level of Bax protein was increased after Phenylacetic Acid treatment at different concentrations. |
| Animal experiment [2]: | |
|
Animal models |
C57BL/6 mice, 6-10 weeks 10-25 g |
|
Preparation Method |
The mice were randomly divided into 3 groups with Phenylacetic Acid group (maximum nonlethal acetic acid group, phenylacetic acid group (750mg/(kg.d)), and the same volume of physiological saline group.The method of administration was subcutaneous injection, once a day, for 2 weeks. |
|
Dosage form |
750mg/(kg.d) Phenylacetic Acid for 2 weeks |
|
Applications |
Phenylacetic Acid can inhibit the growth of salivary gland tumors by inhibiting ERK/MAPK pathway and reduce cell proliferation, which is expected to be used in drug therapy of salivary gland tumors. |
|
References: [1]. Yang Li, et al." Sodium phenylacetic acid induces apoptosis of human leukemia cell HL60 and its mechanism." Shandong Medical Journal 50.40(2010):60-61. |
|
| Cas No. | 103-82-2 | SDF | |
| 别名 | 苯乙酸,NSC 125718, Phenylethanoic acid, α-Toluic acid | ||
| 化学名 | Benzeneacetic acid | ||
| Canonical SMILES | OC(CC1=CC=CC=C1)=O | ||
| 分子式 | C8H8O2 | 分子量 | 136.2 |
| 溶解度 | 1mg/mL in DMF; DMSO: 2mg/mL | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 7.3421 mL | 36.7107 mL | 73.4214 mL |
| 5 mM | 1.4684 mL | 7.3421 mL | 14.6843 mL |
| 10 mM | 0.7342 mL | 3.6711 mL | 7.3421 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet